Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID ‐19 patients with type 2 diabetes: A target trial emulation study

Eric Y. F. Wan, Zoey C. T. Wong, Vincent K. C. Yan, Celine S. L. Chui, Francisco T. T. Lai, Xue Li, Ian C. K. Wong*, Esther W. Y. Chan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: To compare the effectiveness of molnupiravir and nirmatrelvir‐ritonavir for non‐hospitalized and hospitalized COVID‐19 patients with type 2 diabetes (T2DM). Materials and Methods: Territory‐wide electronic health records in Hong Kong were used to perform target trial emulation using a sequential trial approach. Patients (1) aged ≥18 years, (2) with T2DM, (3) with COVID‐19 infection, and (4) who received molnupiravir or nirmatrelvir‐ritonavir within 5 days of infection between 16 March 2022 and 31 December 2022 in non‐hospital and hospital settings were included. Molnupiravir and nirmatrelvir‐ritonavir initiators were matched using one‐to‐one propensity‐score matching and followed for 28 days. Risk of outcomes was compared between groups by Cox regression adjusted for baseline characteristics. Subgroup analyses were performed on age (
Original languageEnglish
Pages (from-to)4653-4664
Number of pages12
JournalDiabetes, Obesity and Metabolism
Volume26
Issue number10
Early online date7 Aug 2024
DOIs
Publication statusPublished - Oct 2024

Bibliographical note

Published CC BY NC

Publisher Copyright:
© 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Data Access Statement

Data are not available as the data custodians (the Hospital Authority and the Department of Health of Hong Kong SAR) have not given permission for sharing due to patient confidentiality and privacy concerns. Local academic institutions, government departments, or non-governmental organizations may apply for the access to data through the Hospital Authority's data sharing portal (https://www3.ha.org.hk/data).

Keywords

  • effectiveness
  • pharmacoepidemiology
  • real-world evidence
  • type 2 diabetes

Fingerprint

Dive into the research topics of 'Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID ‐19 patients with type 2 diabetes: A target trial emulation study'. Together they form a unique fingerprint.

Cite this